- Home
- VNDA
as 06-20-2025 3:43pm EST
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | WASHINGTON |
| Market Cap: | 261.7M | IPO Year: | 2006 |
| Target Price: | $15.33 | AVG Volume (30 days): | 362.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.81 - $6.37 | Next Earning Date: | 07-30-2025 |
| Revenue: | $201,351,000 | Revenue Growth: | 13.37% |
| Revenue Growth (this year): | 16.86% | Revenue Growth (next year): | 39.78% |
Stock Insider Trading Activity of Vanda Pharmaceuticals Inc. (VNDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mitchell Stephen Ray | VNDA | Director | Jun 13 '25 | Sell | $4.59 | 7,000 | $32,130.00 | 97,082 | |
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | May 21 '25 | Buy | $4.40 | 10,000 | $43,995.19 | 2,325,250 | |
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | May 16 '25 | Buy | $4.22 | 20,000 | $84,472.00 | 2,325,250 |
Latest Vanda Pharmaceuticals Inc. News
VNDA Breaking Stock News: Dive into VNDA Ticker-Specific Updates for Smart Investing
PR Newswire
11 days ago
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
PR Newswire
25 days ago
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 05/21/2025
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 05/16/2025
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 05/15/2025
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 05/14/2025
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 05/09/2025
Thomson Reuters StreetEvents
a month ago
Q1 2025 Vanda Pharmaceuticals Inc Earnings Call
Compare VNDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VNDA Vanda Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.